Caixin
Eli Lilly partners with Shanghai Junshi for COVID-19 cure
Deal empowers Chinese company to fast-track promising coronavirus therapies
Deal empowers Chinese company to fast-track promising coronavirus therapies
Drugmaker rolls dice with bulking up capacity before clinical trials launch
Asia’s largest research reagent company supplies enough to test 2 million per month
Hundreds of thousands are expected to be released to develop new treatments
Drugmaker aims for trials this year with eventual goal of 10 million doses
Japanese group conducts genetic analysis, now seeks partners for trials
Japanese biotech company hopes to supply 200,000 people this year
Biotech unit to field clients directly as safety concerns mount
Prudential-backed group targets those worried about risks of visiting hospitals
Challenges pile up for some portfolio companies after a $16.7bn investment loss
Stay ahead with our exclusives on Asia;
the most dynamic market in the world.
Stay ahead with our exclusives on Asia
Get trusted insights from experts within Asia itself.
Get trusted insights from experts
within Asia itself.
Stay ahead with our exclusives on Asia; the most dynamic market in the world.
Get trusted insights from experts
within Asia itself.
Offer ends January 31st
You need a subscription to...
You need a subscription to:
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.